Search
for
Sort by
Research
90-120 / 1000+ resultsresearch Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase
Two existing drugs may help treat COVID-19 by inhibiting a key viral protein.
research A skin organoid-based infection platform identifies an inhibitor specific for HFMD
NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
research Enzalutamide, a prostate cancer therapeutic, downregulates TMPRSS2 in lung and reduces cellular entry of SARS-CoV-2
Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
research WHOLE PLANT ADIANTUM CAPILLUS-VENERIS LINN. EXTRACT AS AN ANTI-COVID-19 THERAPY.
The extract from the plant Adiantum capillus-veneris might be used to treat COVID-19.
research Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
Bromhexine and spironolactone together reduced COVID-19 symptoms and hospitalization time without side effects.
research Nitroxide pharmaceutical development for age-related degeneration and disease
Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
research Cepharanthine: A review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine could be a strong antiviral against COVID-19.
research SARS in Children
Children under 18 had milder SARS with no deaths, but teenagers faced higher severe illness risk, and effective treatments were uncertain.
research AB0697 COMPARISON OF COVID-19 VACCINATION WITH INFLUENZA VACCINATION IN KOREAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PERCEPTION, ADVERSE EVENTS, AND FLARES FROM THE CIVIL STUDY
COVID-19 vaccines had more side effects and worse perception than flu vaccines in Korean lupus patients.
research Clinical outcomes and considerations in outpatient with COVID‐19 receiving remdesivir therapy
Early remdesivir treatment improves outcomes in Covid-19 patients with few side effects.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.
research Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort
Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
research [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].
Some gonadal hormone drugs can block filovirus entry into cells.
research Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects
Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
research Bis-Benzylisoquinoline Alkaloids Inhibit Porcine Epidemic Diarrhea Virus In Vitro and In Vivo
Certain plant compounds can help prevent and treat a virus in pigs.
research Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency Due to an Interaction Between Fluticasone and Ritonavir
A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
research Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.
Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Finasteride Induces Epigenetic Alteration of TMPRss2 Gene Expression: A Potential role in Severe Acute Respiratory Syndrome-Corona Virus-2 Inhibition
Finasteride may help reduce COVID-19 infection by altering a key gene.
research Spiking dependence of SARS‐CoV‐2 pathogenicity on TMPRSS2
TMPRSS2 affects COVID-19 severity and treatment options.
research Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial.
Hydroxychloroquine, nitazoxanide, and ivermectin were similarly effective in treating early COVID-19.
research Drug Information Analysis Service
Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
research Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?
SARS-CoV-2, the virus causing COVID-19, can affect all endocrine organs and systems, altering their function and potentially leading to disorders. Factors like diabetes and obesity increase infection risk and severity. Understanding these effects is key for effective treatment.
research ACUTE TELOGEN EFFLUVIUM FOLLOWING SARS-COV-2 INFECTION: A RARE PEDIATRIC CASE
A 6-year-old girl experienced temporary hair loss after mild COVID-19, which improved naturally in 8 months.
research Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
Infectious virus was not found after the third remdesivir dose, suggesting early end of isolation is possible.
research Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management
Hair loss is a frequent long-term effect of COVID-19, and oral minoxidil is the most common effective treatment.
research Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.